Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase.

CONCLUSION: Chronic refractory gout patients not achieving protocol-defined persistent urate lowering still achieve significant clinical benefits with pegloticase treatment, suggesting that transient reduction in serum urate may result in sustained clinical benefit. PMID: 31203212 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31203212?dopt=Abstract

Source: J Rheumatol - June 14, 2019 Category: Rheumatology Authors: Pillinger MH, Fields T, Yeo AE, Lipsky PE Tags: J Rheumatol Source Type: research

More News: Arthritis | Chronic Pain | Gout | Pain | Rheumatology